Core Viewpoint - The announcement indicates that Jiangsu Bochuangyuan Biopharmaceutical Technology Co., Ltd., a subsidiary of Tiancong, has received approval from the National Medical Products Administration for a seamless adaptive clinical trial of CKBA ointment for the treatment of rosacea, marking a significant step in the development of innovative therapies in the pharmaceutical industry [1] Group 1 - The clinical trial approval is for the II/III phase of the CKBA ointment, which is a locally applied formulation developed independently by Bochuangyuan [1] - CKBA ointment is classified as a Class 1 innovative chemical drug, featuring a novel structure, independent intellectual property rights, a clear mechanism of action, and good safety profile [1] - The company aims to initiate the clinical trial as soon as possible, and if approved, the product could provide innovative and safe treatment options for patients, highlighting its social significance and economic value [1]
泰恩康：CKBA乳膏获药物临床试验批准通知书